Videos

A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.

Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.

The executive director of Banner Alzheimer’s Institute discussed the future of blood tests as a biomarker that may help in addressing current challenges, including drug development.

Panelists look ahead in the management of advanced Parkinson disease and discuss the promise of different investigational therapies.

Neurology News Network for the week ending August 7, 2021.

A discussion about the benefits of a multidisciplinary evaluation for patients with advanced Parkinson disease who are potential candidates for device-assisted therapy.

The executive director of Banner Alzheimer’s Institute commented on ongoing research into amyloid plaque-reducing antibody therapies, the approval of aducanumab, and other initiatives with the ability to impact the treatment of Alzheimer disease.

The assistant professor at Cleveland Clinic provided thoughts on the barriers clinicians face when formulating and conducting Alzheimer disease clinical trials with repurposed drugs.

James Wymer, MD discusses his firsthand experience with risdiplam and identifies a key unmet need in the treatment of spinal muscular atrophy.

An expert neurologist emphasizes the importance of medication compliance and the value of multidisciplinary management in meeting patient goals of therapy for spinal muscular atrophy.

Arun S. Varadhachary, MD, PhD shares insights into clinicians’ and patients’ experiences with medical therapy, comments on unmet needs for adult patients, and speculates about the future of SMA care.

The professor of neurology at the Mayo Clinic College of Medicine discussed the need for evaluating infection risk of disease-modifying therapies amid a growing MS treatment landscape.

The executive director of Banner Alzheimer’s Institute discussed the current state of AD trials, as well as his perspective on ongoing efforts to establish prevention therapies.

The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.

The president of the American Heart Association discussed the necessary steps to increase access to systems of care in order to improve health overall, including the integration of telemedicine.

A scientific statement and updated guidelines for stroke prevention were both published this year by the American Heart Association and the American Stroke Association; Mitchell S.V. Elkind, MD, MS, MPhil, discusses how the 2 coincide.

Episode 13 of the AUPN Leadership Minute features Muhammad “Mud” Alvi, MD, of West Virginia University; and Barbara G. Vickrey, MD, MPH, of Icahn School of Medicine at Mount Sinai. [WATCH TIME: 4 minutes]

The president of the American Heart Association commented on the integral aspect of collaboration between specialists and providers when it comes to poststroke care.

The president of the American Heart Association spoke on educating primary care physicians about poststroke care for adults, following the publication of new guidelines for care to foster long-term prevention.

The assistant professor of neurology at Harvard Medical School discussed why there isn’t just a “one size fits all” approach to treating cranial neuralgias.

Michael J. Soileau, MD, discusses the challenges of starting a device-assisted therapy in patients with advanced Parkinson disease.

An advanced Parkinson disease expert explains how to discuss the different device-assisted therapy options with patients.

Joseph Sullivan, MD, and Elaine C. Wirrell, discuss the transition of care into adulthood of patients with Dravet syndrome.

Key opinion leaders discuss managing patient expectations regarding clinical trials for Dravet syndrome treatment.

Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.

Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.

Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.

An insight into the goals of therapy and treatment selection between oral and intrathecal medications for adult-onset spinal muscular atrophy.

A discussion of the multidisciplinary treatment approach in spinal muscular atrophy.